Keyphrases
1-year Mortality
14%
Acinetobacter Baumannii (A. baumannii)
22%
Active Surveillance
19%
Acute Hospital
12%
Antimicrobial Resistance
27%
Bacteremia
35%
Bloodstream Infection
67%
Carbapenem Resistance
24%
Carbapenem-resistant Acinetobacter Baumannii
57%
Carbapenem-resistant Enterobacteriaceae
27%
Carbapenemases
20%
Cholesterol
13%
Clinical Characteristics
18%
Clostridium Difficile Infection
18%
Colistin
13%
Confidence Interval
14%
Dextran Sulfate Sodium
18%
Enterobacteriaceae
14%
Erythrocytes
20%
Escherichia Coli
56%
Extended-spectrum-lactamase
19%
Fecal Carriage
20%
Fibrinogen
13%
Fourier Transform Infrared Spectroscopy (FT-IR)
13%
Hospital Admission
28%
Hospital-onset
23%
Hospitalized Patients
19%
Infection Control
13%
Israel
96%
Israeli
16%
Klebsiella Pneumoniae (K. pneumoniae)
15%
KPC-2
19%
LDL Apheresis
13%
Lipoproteins
13%
Multidrug-resistant
13%
National Cohort Study
19%
Neonatal Intensive Care Unit
38%
Odds Ratio
14%
OXA-48
18%
Peripheral Blood
22%
Plasmid
14%
Population-based Study
18%
Producing Escherichia Coli
17%
Pseudomonas Aeruginosa (P. aeruginosa)
21%
Red Blood Cell Aggregation
18%
Risk Factors
38%
Sentinel
17%
Staphylococcus Aureus
14%
Tel Aviv
17%
Vancomycin-resistant Enterococci
19%
Medicine and Dentistry
Acinetobacter Baumannii
48%
Antibiotic Resistance
30%
Atherosclerosis
9%
Beta-Lactamase
11%
Bloodstream Infection
62%
Carbapenem
52%
Carbapenem-Resistant Enterobacteriaceae
27%
Carbapenemase
19%
Clostridium Difficile Infection
9%
Cohort Analysis
10%
Cohort Effect
11%
Congenital Tuberculosis
9%
COVID-19
9%
DNA Sequence
9%
Effusion
9%
Endoscope
9%
Enterobacteriaceae
11%
Enterococcus faecium
20%
Escherichia coli
48%
Extended Spectrum Beta Lactamase
12%
Extended Spectrum Beta Lactamase Producing Escherichia Coli
9%
Extended Spectrum Beta Lactamase Producing Klebsiella Pneumoniae
9%
Genome Sequencing
9%
Heat Tolerance
9%
Hysterectomy
11%
Infection
37%
Infection Control
21%
Intensive Care
12%
Intensive Care Unit
17%
Laboratory Diagnosis
9%
LDL Apheresis
9%
Meningitis
9%
Neonatal Intensive Care Unit
27%
Newborn Intensive Care
11%
Odds Ratio
10%
Pathogen
18%
Patient Isolation
9%
Penicillinase
21%
Peptoclostridium difficile
9%
Peripheral Vascular Disease
9%
Prevalence
12%
Ribosome DNA
9%
Risk Perception
9%
Sepsis
11%
Staphylococcus Aureus
10%
Subacute Care
11%
Thorax Radiography
9%
Vancomycin Resistant Enterococcus
19%
Wound
11%
Wound Infection
9%
Pharmacology, Toxicology and Pharmaceutical Science
2009 H1N1 Influenza
9%
Acinetobacter Baumannii
40%
Acinetobacter Infection
6%
Adverse Outcome
11%
Antibiotics
8%
Antimicrobial Resistance
37%
Antimicrobial Therapy
12%
Atherosclerosis
9%
Bacterial Infection
9%
Bloodstream Infection
100%
Carbapenem
33%
Carbapenemase
18%
Case Fatality Rate
8%
Cerivastatin
9%
Clostridium Difficile Infection
9%
Cohort Study
10%
Comorbidity
10%
Coronavirinae
9%
Dextran Sulfate
9%
Diarrhea
9%
Diclofenac
9%
Diseases
11%
Enterobacter
9%
Enterobacteriaceae
12%
Enterococcus faecalis
5%
Escherichia coli
53%
Extended Spectrum Beta Lactamase
18%
Fibrinogen
9%
Fourier Transform Infrared Spectroscopy
9%
Gram Negative Sepsis
9%
Homocysteine
9%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
5%
Hypercholesterolemia
10%
Infection
38%
Infectious Agent
8%
Klebsiella
10%
Lactam
11%
Lipoprotein
9%
Low Density Lipoprotein
9%
Lung Tuberculosis
9%
Microorganism
9%
Penicillinase
21%
Peptoclostridium difficile
9%
Prevalence
10%
Pseudomonas aeruginosa
23%
Quinolone Derivative
9%
Rhabdomyolysis
9%
Staphylococcus Aureus
13%
Syndrome
10%
Wound Infection
9%